← Back to Search

Antipsychotic/Antidepressant Combination

Multiple Medications for Bipolar Depression (SMART-BD Trial)

Phase 4
Waitlist Available
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aged between 18 years to 75 years
Meets criteria for DSM-V Bipolar I disorder with a history of manic episodes and current major depressive episode lasting at least 6 weeks
Must not have
Meets current criteria for a manic episode, rapid cycling within the past year (history of 4 or more mood episodes per year)
A history of non-response for depressive episodes, to any of the study medications, when given at adequate doses for at least 6 weeks
Timeline
Screening 3 weeks
Treatment Varies
Follow Up investigators will administer this measure every 2 weeks for the first 12 weeks (weeks:0,2,4,6,8,10,12), and then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
Awards & highlights

Summary

"This trial is testing four different treatments for adults with bipolar disorder type 1 who are currently feeling depressed. The treatments being compared are Cariprazine, Quetiapine, Lurasidone

Who is the study for?
Adults over 18 with bipolar disorder type 1 who are currently in a depressive episode can join this trial. It's not specified, but typically participants need to meet certain health criteria and may be excluded for various reasons such as other medical conditions or treatments that could interfere with the study.
What is being tested?
The trial is testing four treatments for bipolar depression: Cariprazine, Quetiapine, Lurasidone (all FDA-approved), and an Aripiprazole/Escitalopram combo. Patients will be randomly assigned to one of these treatments in sequence to see which works best.
What are the potential side effects?
Possible side effects from these medications might include dizziness, sleepiness, weight gain, digestive issues, restlessness or agitation. Each medication has its own set of potential side effects that can vary from person to person.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 75 years old.
Select...
I have been diagnosed with Bipolar I disorder and am currently experiencing a major depressive episode that has lasted for at least 6 weeks.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have experienced rapid mood changes, including 4 or more episodes in the last year.
Select...
My depression didn't improve after 6 weeks on certain medications.
Select...
I am not currently at risk of suicide requiring hospitalization.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~investigators will administer this measure every 2 weeks for the first 12 weeks (weeks:0,2,4,6,8,10,12), and then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
This trial's timeline: 3 weeks for screening, Varies for treatment, and investigators will administer this measure every 2 weeks for the first 12 weeks (weeks:0,2,4,6,8,10,12), and then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ). for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The Remission from Depression Questionnaire
Secondary study objectives
Frequency and Intensity of Side Effects Ratings - Burden
Frequency and Intensity of Side Effects Ratings - Frequency
Frequency and Intensity of Side Effects Ratings - Intensity
+1 more
Other study objectives
Altman Self-Rating Mania Scale
Generalized Anxiety Disorder Assessment
Medication Reconciliation Tracking Form
+5 more

Trial Design

4Treatment groups
Experimental Treatment
Group I: QuetiapineExperimental Treatment1 Intervention
Group II: LurasidoneExperimental Treatment1 Intervention
Group III: CariprazineExperimental Treatment1 Intervention
Group IV: Aripiprazole /Escitalopram combinationExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cariprazine
2010
Completed Phase 3
~11050
Quetiapine
2003
Completed Phase 4
~3220
Lurasidone
2008
Completed Phase 4
~4600

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,993 Previous Clinical Trials
13,227,995 Total Patients Enrolled
70 Trials studying Bipolar Disorder
15,544 Patients Enrolled for Bipolar Disorder
Patient-Centered Outcomes Research InstituteOTHER
568 Previous Clinical Trials
27,246,683 Total Patients Enrolled
6 Trials studying Bipolar Disorder
1,043,174 Patients Enrolled for Bipolar Disorder
~1817 spots leftby Feb 2030
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top